{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:09:32Z","timestamp":1748923772565,"version":"3.41.0"},"reference-count":18,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.3892\/br.2016.660","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T12:52:40Z","timestamp":1461070360000},"page":"664-666","source":"Crossref","is-referenced-by-count":1,"title":["Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals"],"prefix":"10.3892","volume":"4","author":[{"given":"TORU","family":"ISHIKAWA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SATOSHI","family":"ABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKAYUKI","family":"WATANABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUJIRO","family":"NOZAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOE","family":"SANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKITO","family":"IWANAGA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEIICHI","family":"SEKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TERASU","family":"HONMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOSHIAKI","family":"YOSHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"issue":"Suppl 1","key":"key20180107141153_b1-br-0-0-660","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1002\/hep.1840360719","article-title":"Monitoring of viral levels during therapy of hepatitis C","volume":"36","author":"Davis","year":"2002","journal-title":"Hepatology"},{"key":"key20180107141153_b2-br-0-0-660","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon","volume":"37","author":"Herrmann","year":"2003","journal-title":"Hepatology"},{"key":"key20180107141153_b3-br-0-0-660","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"key20180107141153_b4-br-0-0-660","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"key":"key20180107141153_b5-br-0-0-660","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.21265","article-title":"HALT-C Trial Group: HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial","volume":"44","author":"Morishima","year":"2006","journal-title":"Hepatology"},{"key":"key20180107141153_b6-br-0-0-660","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2005.08.016","article-title":"Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse","volume":"44","author":"Gerotto","year":"2006","journal-title":"J Hepatol"},{"key":"key20180107141153_b7-br-0-0-660","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"key20180107141153_b8-br-0-0-660","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000315234","article-title":"Diagnostic and treatment algorithm of the Japanese society of hepatology: A consensus-based practice guideline","volume":"78","author":"Izumi","year":"2010","journal-title":"Oncology"},{"key":"key20180107141153_b9-br-0-0-660","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"ADVANCE Study Team: Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107141153_b10-br-0-0-660","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107141153_b11-br-0-0-660","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"REALIZE Study Team: Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107141153_b12-br-0-0-660","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology"},{"key":"key20180107141153_b13-br-0-0-660","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","article-title":"Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan","volume":"56","author":"Kumada","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"key20180107141153_b14-br-0-0-660","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/liv.12715","article-title":"Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C","volume":"35","author":"Welch","year":"2015","journal-title":"Liver Int"},{"key":"key20180107141153_b15-br-0-0-660","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","article-title":"Simeprevir with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial","volume":"61","author":"Hayashi","year":"2014","journal-title":"J Hepatol"},{"key":"key20180107141153_b16-br-0-0-660","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","article-title":"Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies","volume":"49","author":"Izumi","year":"2014","journal-title":"J Gastroenterol"},{"key":"key20180107141153_b17-br-0-0-660","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/hepr.12375","article-title":"Simeprevir (TMC435) once daily with peginterferon-\u03b1-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study","volume":"45","author":"Kumada","year":"2015","journal-title":"Hepatol Res"},{"key":"key20180107141153_b18-br-0-0-660","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/hepr.12475","article-title":"Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b hepatitis C virus infection according to an algorithm based on the drug Adherence, IL-28B Gene Allele and Viral Response Trial (AG & RGT)","volume":"45","author":"Sugawara","year":"2015","journal-title":"Hepatol Res"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/br.2016.660\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T20:19:08Z","timestamp":1748895548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2016.660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,4,19]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.3892\/br.2016.660"],"URL":"https:\/\/doi.org\/10.3892\/br.2016.660","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"type":"print","value":"2049-9434"},{"type":"electronic","value":"2049-9442"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}